SCHEMBL2732833

SCHEMBL2732833

CCCCCCCCCCCCCCCCOCC(CO)OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 4/20 0.65
USP2 O75604 1/20 0.56
ADRA1D P25100 1/20 0.53
PTAFR P25105 1/20 0.53
HTR1D P28221 1/20 0.53
HTR2C P28335 1/20 0.53
ADRA1B P35368 1/20 0.53
DRD3 P35462 1/20 0.53
TMEM97 Q5BJF2 1/20 0.53
PRKCE Q02156 1/20 0.51
PRKCQ Q04759 1/20 0.51
PRKCD Q05655 1/20 0.51
PLA2G2C Q5R387 2/20 0.50
CES2 O00748 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27795601 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL5493689 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL1008410 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL7411764 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL1009136 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL9436412 0.98 PRKCA (0.62) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL4324597 0.93 PRKCA (0.59) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL4912502 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL4912512 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL1000470 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006492-A None JP disclosed
JP-2006493-A None JP disclosed
US-11479802-B2 Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family REGENERON PHARMACEUTICALS, INC. (US) 2022-10-25 US disclosed
EP-3610029-A1 ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY Regeneron Pharmaceuticals, Inc. (US) 2020-02-19 EP disclosed
WO-2018190970-A1 ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY REGENERON PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed
US-20180291422-A1 Assays For Screening Activity Of Modulators Of Members Of The Hydroxysteroid (17-Beta) Dehydrogenase (HSD17B) Family REGENERON PHARMACEUTICALS, INC. 2018-10-11 US disclosed
CN-105441385-A Effective method for generating animal and embryonic stem cells of reprogramming differentiation cells and reprogramming cells ADVANCED CELL TECH INC 2016-03-30 CN disclosed
CN-103827075-B The preparation method of 1-palmityl-3-ethanoyl glycerine and use it to prepare the method for 1-palmityl-2-sub-oleoyl-3-ethanoyl glycerine ENZYCHEM LIFESCIENCES CORP. (KR) 2015-09-16 CN disclosed
CN-103827075-A Preparation method of 1-palmitoyl-3-acetylglycerol, and preparation method of 1-palmitoyl-2-linoleoyl-3-acetylglycerol using same ENZYCHEM LIFESCIENCES CORP 2014-05-28 CN disclosed
US-7906147-B2 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2011-03-15 US disclosed
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2008-04-17 US disclosed
US-6562804-B2 For stimulating hair growth in a mammal KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-05-13 US disclosed
US-20020172657-A1 Hair-growing agent KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-11-21 US disclosed
EP-1232740-A2 Hair-growing agent KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-21 EP disclosed
EP-0284395-B1 NOVEL GLYCEROL DERIVATIVE AND ANTI-HYPERTENSIVE AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 1993-06-23 EP disclosed
US-5183811-A Glycerol derivative and anti-hypertensive agent NIPPON CHEMIPHAR CO., LTD. (JP) 1993-02-02 US disclosed
US-4962096-A WITH REDUCED PLATELET AGGREGATING ACTION NIPPON CHEMIPHAR CO., LTD. (JP) 1990-10-09 US disclosed
JP-H026492-A NOVEL GLYCEROL DERIVATIVE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DERIVATIVE NIPPON CHEMIPHAR CO LTD 1990-01-10 JP disclosed
JP-H026493-A NOVEL GLYCEROL DERIVATIVE, ITS PRODUCTION AND HYPOTENSOR CONTAINING THE SAME DERIVATIVE NIPPON CHEMIPHAR CO LTD 1990-01-10 JP disclosed
EP-0284395-A2 Novel glycerol derivative and anti-hypertensive agent NIPPON CHEMIPHAR CO., LTD. (JP) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020172657-A1 Hair-growing agent PHOSPHO1, PLD1, SGMS1 PRKCA 2499/4885USP2 2204/4885ADRA1D 2888/4885
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography TFRC, FABP1, SCARB1 PRKCA 2358/4885USP2 1613/4885ADRA1D 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.